ArticleCureus2025
Occult Hypercalcemia Unmasked: Insights From Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Syndrome Associated With a Gastrointestinal Lymphoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is a rare inflammatory arthritis that may present as a paraneoplastic syndrome. We report a case of a 51-year-old woman who initially responded to high-dose steroids for RS3PE but later developed persistent hypercalcemia. Serum calcium ranged from 3.03 to 4.02 mmol/L, with suppressed parathyroid hormone (PTH), suggesting a non-parathyroid cause. Despite initial suspicion of infection-related hypercalcemia, calcium levels remained elevated after antimicrobial therapy. The 25-hydroxyvitamin D level was elevated, although serum 1,25-dihydroxyvitamin D was not directly measured. Immunohistochemistry revealed strong expression of parathyroid hormone-related protein (PTHrP) and 25-hydroxyvitamin D3-1α-hydroxylase (CYP27B1), indicating potential contributions from both humoral and vitamin D-mediated pathways. The patient received supportive treatment with diuretics, calcitonin, and denosumab, which successfully corrected hypercalcemia. Gastrointestinal endoscopy and biopsy ultimately confirmed diffuse large B-cell lymphoma (DLBCL). She then underwent anti-lymphoma chemotherapy, resulting in sustained remission and stable calcium levels. This case highlights the diagnostic challenges of RS3PE with hypercalcemia and the importance of considering underlying malignancy when standard therapy fails. It also demonstrates that PET-CT may fail to detect tumors in hollow organs and that gastrointestinal endoscopy should be considered in unresolved cases. Early recognition of tumor-associated hypercalcemia and a mechanism-based diagnostic approach are essential for effective treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.